SAFETY DATA SHEET

SECTION 1. IDENTIFICATION

Product Identifier: (3N) 99.9% Manganese Iron Oxide Nanopowder
Product Code: MN-FEO-03-NP
CAS Number: 12063-10-4
Relevant identified uses of the substance: Scientific research and development

Supplier details:
American Elements
10884 Weyburn Ave.
Los Angeles, CA 90024
Tel: +1 310-208-0551
Fax: +1 310-208-0351
Emergency telephone number:
+1 800-424-9300

SECTION 2. HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture
Not a hazardous substance or mixture.
2.2 GHS Label elements, including precautionary statements
Not a hazardous substance or mixture.
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances
Synonyms: Manganese ferrite
Iron manganese oxide
Iron manganese spinel
Formula: MnFe2O4
Molecular weight: 230.63 g/mol
CAS-No.: 12063-10-4
EC-No.: 269-056-3
Hazardous components
Component Classification Concentration
Iron manganese oxide
SECTION 4. FIRST AID MEASURES

4.1 Description of first aid measures
General advice
Move out of dangerous area.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
4.2 Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11
4.3 Indication of any immediate medical attention and special treatment needed
No data available

SECTION 5. FIREFIGHTING MEASURES

5.1 Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
5.2 Special hazards arising from the substance or mixture
Iron oxides, Manganese/manganese oxides
5.3 Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
5.4 Further information
No data available

SECTION 6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing Vapors, mist or gas.
For personal protection see section 8.
6.2 Environmental precautions
Do not let product enter drains.
6.3 Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
6.4 Reference to other sections
For disposal see section 13.

SECTION 7. HANDLING AND STORAGE

7.1 Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2.

7.2 Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place.

7.3 Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters
Components with workplace control parameters
Component CAS-No. Value Control parameters
Basis
Iron manganese oxide
12063-10-4 C 5.000000 mg/m3
USA. Occupational Exposure Limits
(OSHA) - Table Z-1 Limits for Air Contaminants
Remarks Ceiling limit is to be determined from breathing-zone air samples.
TWA 0.200000 mg/m3
USA. ACGIH Threshold Limit Values (TLV)
Central Nervous System impairment
Adopted values or notations enclosed are those for which changes vary
TWA 1.000000 mg/m3
USA. NIOSH Recommended Exposure Limits
ST 3.000000 mg/m3
USA. NIOSH Recommended Exposure Limits
TWA 0.100000 mg/m3
USA. ACGIH Threshold Limit Values (TLV)
Central Nervous System impairment
2015 Adoption varies
TWA 0.020000 mg/m3
USA. ACGIH Threshold Limit Values (TLV)
Central Nervous System impairment
2015 Adoption varies
C 5 mg/m³ USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
Ceiling limit is to be determined from breathing-zone air samples.
TWA 0.1 mg/m³ USA. ACGIH Threshold Limit Values (TLV)
Central Nervous System impairment
Not classifiable as a human carcinogen
varies
TWA 0.02 mg/m³ USA. ACGIH Threshold Limit Values (TLV)
Central Nervous System impairment
Not classifiable as a human carcinogen
varies
TWA 1 mg/m³ USA. NIOSH Recommended Exposure Limits
ST 3 mg/m³ USA. NIOSH Recommended Exposure Limits
8.2 Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the specific workplace. The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odor No data available
c) Odor Threshold No data available
SECTION 10. STABILITY AND REACTIVITY

10.1 Reactivity
No data available

10.2 Chemical stability
Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions
No data available

10.4 Conditions to avoid
No data available

10.5 Incompatible materials
No data available

10.6 Hazardous decomposition products
Other decomposition products - No data available

In the event of fire: see section 5

SECTION 11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects
Acute toxicity
No data available
Inhalation: No data available
Dermal: No data available
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
Carcinogenicity

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
No data available

Specific target organ toxicity - single exposure
No data available

Specific target organ toxicity - repeated exposure
No data available

Aspiration hazard
No data available

Additional Information

RTECS: Not available

Men exposed to manganese dusts showed a decrease in fertility. Chronic manganese poisoning primarily involves the central nervous system. Early symptoms include languor, sleepiness and weakness in the legs. A stolid mask-like appearance of the face, emotional disturbances such as uncontrollable laughter and a spastic gait with tendency to fall in walking are findings in more advanced cases. High incidence of pneumonia has been found in workers exposed to the dust or fume of some manganese compounds. To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

Stomach - Irregularities - Based on Human Evidence
Stomach - Irregularities - Based on Human Evidence

SECTION 12. ECOLOGICAL INFORMATION

12.1 Toxicity
No data available

12.2 Persistence and degradability
No data available

12.3 Bioaccumulative potential
No data available

12.4 Mobility in soil
No data available

12.5 Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6 Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods

SECTION 15. REGULATORY INFORMATION

SARA 302 Components
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

SARA 313 Components
The following components are subject to reporting levels established by SARA Title III, Section 313:
Iron manganese oxide
CAS-No. 12063-10-4
Revision Date 2007-07-01

SARA 311/312 Hazards
Chronic Health Hazard

Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know Components
Iron manganese oxide
CAS-No. 12063-10-4
Revision Date 2007-07-01

New Jersey Right To Know Components
Iron manganese oxide
CAS-No. 12063-10-4
Revision Date 2007-07-01

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.

16. OTHER INFORMATION

Safety Data Sheet according to Regulation (EC) No. 1907/2006 (REACH). The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The